Media Releases
» Go to news mainMedia Opportunity: Harnessing COVID‑19 for cancer therapy? Scientists hopeful they can repurpose anti‑SARS‑CoV‑2 immune response to kill cancers
COVID-19 has touched almost every country around the world since it emerged months ago, leaving hundreds of thousands dead and millions infected with the SARS-CoV-2 virus. But there might be a silver lining to this catastrophic pandemic.
Dr. Shashi Gujar, a scientist with the Department of Pathology, Faculty of Medicine at Dalhousie University, who is leading an ongoing international collaboration with partners in France, Denmark, Germany, US and India, is examining whether the body’s immune response to SARS-CoV-2 could be repurposed to kill cancer cells.
Following infection with SARS-CoV-2, our defence system -- the immune system -- recognizes the virus and activates a particular type of immune cell called “T cells.” These T cells act in a highly precise manner and kill only virus-harbouring cells. Most importantly, T cells can establish a ‘memory’ response that maintains active protection against possible re-infection with the virus.
As a result, SARS-CoV-2-specific T cells can hunt for the virus inside the body, eliminate the niches where the virus replicates and aid in recovery from COVID-19. Interestingly, multiple COVID-19 vaccines that are being tested internationally have shown similar capacity to activate SARS-CoV-2-specific T cells. In the aftermath of the COVID-19 pandemic, SARS-CoV-2-specific T cells -- induced by either infection or vaccinations -- will be found in millions of people worldwide.
The T cells generated in response to the viral infection remain in the body for a long time and Dr. Gujar and his scientific partners believe that these virus-specific T cells could be redirected to go after cancer cells. With the initial support from Dalhousie Medical Research Foundation, the team has started work on repurposing SARS-CoV-2-specific T cells to target cancers of various types, as outlined in their recently published article in the journal OncoImmunology.
Dr. Gujar is available to explain the research and the potential promise of exploiting anti-COVID-19 immunity to destroy cancer cells in what could be the next generation of cancer immunotherapy.
Media contact:
Alison Auld
Senior Research Reporter
Dalhousie University
Alison.auld@dal.ca
Mobile: 902-220-0491
Recent News
- Media opportunity: Being involved in extracurricular activities really does matter when it comes to 'mattering': Dalhousie University research
- Media opportunity: Podcast by Dalhousie researcher and Halifax photographer looks at barriers to Nova Scotia's coastline, decreasing access to waterfronts and problems with litter, marine debris in public coastal areas
- Media opportunity: Dalhousie University researcher pioneers new cancer treatment ‑‑ cutting‑edge CAR‑T cell therapy
- Media opportunity: Research sheds light on the difficulty temporary foreign workers can face in securing permanent residency in P.E.I.
- Media opportunity: World's largest stores of unfrozen freshwater projected to warm and affect cold‑water habitats, geothermal energy resources and drinking water quality : Dalhousie University research
- Media release: Dalhousie University research reveals conservation benefits are doubled for reef sharks and rays in fully protected marine areas that also have strong fisheries management
- Media release: New program partners Dalhousie researcher and IWK Health to tackle violence against women
- Media opportunity: Dalhousie University researchers and an international team identify new strain of mpox virus in Africa that can spread through heterosexual sex and community contact
Comments
comments powered by Disqus